- Home
- REVBW vs MATV Comparison
REVBW vs MATV Comparison
Compare REVBW & MATV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REVBW
- MATV
- Stock Information
- Founded
- REVBW N/A
- MATV 1995
- Country
- REVBW United States
- MATV United States
- Employees
- REVBW 9
- MATV N/A
- Industry
- REVBW Biotechnology: Pharmaceutical Preparations
- MATV Paper
- Sector
- REVBW Health Care
- MATV Basic Materials
- Exchange
- REVBW Nasdaq
- MATV Nasdaq
- Market Cap
- REVBW N/A
- MATV N/A
- IPO Year
- REVBW 2020
- MATV 1995
- Fundamental
- Price
- REVBW $0.02
- MATV $6.86
- Analyst Decision
- REVBW
- MATV Hold
- Analyst Count
- REVBW 0
- MATV 1
- Target Price
- REVBW N/A
- MATV $15.50
- AVG Volume (30 Days)
- REVBW N/A
- MATV 523.4K
- Earning Date
- REVBW N/A
- MATV 02-19-2025
- Dividend Yield
- REVBW N/A
- MATV 5.83%
- EPS Growth
- REVBW N/A
- MATV N/A
- EPS
- REVBW N/A
- MATV N/A
- Revenue
- REVBW N/A
- MATV $1,981,100,000.00
- Revenue This Year
- REVBW N/A
- MATV $1.43
- Revenue Next Year
- REVBW N/A
- MATV $1.80
- P/E Ratio
- REVBW N/A
- MATV N/A
- Revenue Growth
- REVBW N/A
- MATV N/A
- 52 Week Low
- REVBW N/A
- MATV $6.25
- 52 Week High
- REVBW N/A
- MATV $19.96
- Technical
- Relative Strength Index (RSI)
- REVBW N/A
- MATV 21.25
- Support Level
- REVBW N/A
- MATV $8.61
- Resistance Level
- REVBW N/A
- MATV $9.47
- Average True Range (ATR)
- REVBW 0.00
- MATV 0.52
- MACD
- REVBW 0.00
- MATV -0.12
- Stochastic Oscillator
- REVBW 0.00
- MATV 18.89
About REVBW Revelation Biosciences Inc. Warrant
Revelation Biosciences Inc is a clinical-stage life sciences company focused on the development of therapies for the prevention and treatment of disease using trained immunity. It is developing a pipeline of potential high-value products based on Gemini. Gemini is Revelation's proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD) an established TLR4 agonist that can stimulate the human body's innate immune response to prevent and treat disease. The product candidates are developed are based on Gemini formulation of PHAD. Gemini based programs consist of: Gemini-SSI developed for the prevention of surgical site infection (SSI); Gemini-AKI developed for the prevention of acute kidney injury (AKI); and Gemini-CKD for the treatment of chronic kidney disease (CKD).